The recognition of replicating hepatitis B virus (HBV) may be important to both define the cause of and know how to manage chronic liver disease in multitransfused hemophilic patients. Replicating HBV can be detected at the molecular level by methods for HBV-specific DNA (HBV-DNA), which are much more sensitive than the immunologic methods for detecting hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg). Unselected hemophilic patients (260; 6% with HBsAg, 4% with isolated anti-hepatitis B core (anti-HBc), 52% with anti-HBs and anti-HBc, 26% with isolated anti-HBs, and 12% with no HBV marker) were investigated retrospectively with a dot spot hybridization technique that detects serum HBV-DNA down to 0.5 pg and by Southern blot analysis, which tests the specificity of
H cause of morbidity in multitransfused hemophilic patients, even in this era of clotting factor concentrates treated with virucidal methods.' Approximately 10% of multitransfused hemophiliacs are chronic carriers of hepatitis B surface antigen (HBsAg) as a consequence of lifelong exposure to infectious concentrate^.^^^ Chronic HBsAg carriers with elevated serum transaminases fall into two categories. In one category are patients with overt HBV replication, as indicated by hepatitis B e antigen (HBeAg) in serum and hepatitis B core antigen (HBcAg) in the l i~e r .~.~ This virologic profile, which, with few exceptions, is associated with HBV-dependent liver disease, may be time-limited by seroconversion to antibody to HBeAg (anti-HBe), which leads to suppression of HBV replication.6 For the other category, HBsAg carriers who have circulating anti-HBe, ie, a marker of suppressed HBV replication, the etiology of chronic liver disease is less certain. In these carriers, liver disease has been attributed to hepatotoxic factors other than HBV, such as the delta virus, the non-A, non-B viruses, drugs, autoimmunity, or alcoh01.~ However, recent studies have clearly demonstrated that a subset of HBsAg carriers harbor HBV with circulating anti-HBe. In these, cryptic replication of HBV has been linked to preferential localization of HBcAg in the cytoplasm of infected hepatocytes and with the probability of progression of liver disease to c i r r h o~i s .~~~ HBV-DNA sequences have also been found in the serum and liver of HBsAg-seronegative patients with These and other findings suggest that the role of HBV in chronic hepatitis may be greater than previously thought. With the advent of antiviral treatment of chronic hepatitis B, detection of cryptic HBV infection may be important not only for definition of the etiology but also for the management of chronic liver disease in hemophiliacs. Therefore, we looked for HBV-DNA in the sera of 260 unselected hemophiliacs attending our clinic.
MATERIALS AND METHODS
We looked for HBV-DNA in serum samples from 260 unselected hemophilic patients attending the A. Bianchi Bonomi Hemophilia and Thrombosis Center of the University of Milan. They were all male, 2 to 71 years of age (mean, 28). Of the 260 patients, 209 had hemophilia A, 51 had hemophilia B. The clotting defect was severe (factor VI11 or IX, less than 1%) in 176, moderate (between 1% and 5%) in 34, and mild (higher than 5%) in the remaining 50 patients. Table 1 shows other characteristics of these patients. Of 260 patients, 244 had been infused lifelong with clotting factor concentrates, either for prophylaxis or for treating bleeding episodes; the remaining 16 patients were never treated with blood products. Of the 244 treated patients, 227 had been given unmodified concentrates until 1985. Since 1985, these patients were infused exclusively with concentrates for which viral inactivation was attempted by various heating procedures (dry-heating, hot vapor or pasteurization). Serum samples for HBV-DNA assay were obtained at least 2 weeks after infusion with clotting factor concentrates. The remaining 17 patients had been treated exclusively with heated concentrates. Fifty-five patients have had an average annual cumulative exposure to clotting factor concentrates greater than 30,000 IU (intensively treated); 61, between 10,000 and 30,000 IU (moderately treated); and 111, less than 10,000 IU (mildly treated). Table 2 shows the serum profiles of HBV markers for the whole group of patients. Fifteen patients (6%) were chronic (greater than 1 year) HBsAg carriers; 135 patients (52%) had both serum anti-HBc and anti-HBs; 68 patients (26%) had isolated anti-HBs, 35 of them with naturally occurring anti-HBs and 33 who developed anti-HBs after vaccination against HBV (Hevac B, Pasteur, Sausfi, Paris, France; or Engerix B, SKF, Prixeusart, Belgium); 11 patients (42%) had isolated antibody to core antigen (anti-HBc); and 31 patients (12%) had no HBV marker. Eighty-five patients (33%) were anti-human immunodeficiency virus (HIV) seropositive. Of these, six had constitutional symptoms (fever, weight loss), and seven had full-blown AIDS.
The
Patients.
Serum HBV and HIV markers and liver function tests. 
RESULTS
Eighteen patients (7%) tested repeatedly positive for serum HRV-DNA (Table 3 ). Five were HBsAg-positive (three with HReAg. two with anti-HRe). six had both anti-HBs and anti-HBc. five had isolated anti-HBs (including two vaccinees). and two had isolated anti-Hk. HRV-DVA was detected in none of the 31 patients who did not have HBV markers. HRV-DNA was detected more frequently in HRsAg carriers than in HRsAg-negative patients with antibodies to HRV ( 5 of 15.33%. versus 13 of 214.6'70. and t r a m ( 2 ) in 13 HRsAg seronegative patients with antibodies to HRV. The presence of free HRV genome was confirmed in all the HRV-DNA positive sera by Southern blot analysis (Fig 2) . The prevalence of HBV-DNA was not influenced by patient age, severity of coagulation defect or intensity of previous treatments. nor by elevated levels of ALT or HIV infection (Table 3) mained persistently negative for HBsAg and anti-Hk. The other patient was found to be HRV-DNA positive 2 years after the booster dose of vaccine, coincident with a period of heavy e x p u r e to plasma concentrates.
DISCUSSION
Serum HBV-DNA is a sensitive and specific marker of HRV infection that is correlated quantitatively with the replicating activity of the hepatitis virus in the liver." Consistent with previous data for non-hemophilic patients. our study indicates that serum HRV-DNA is more sensitive than the R I A for HBeAg for detecting patients with replicating HRV (7Rnversus 1.1%. P < .01). In fact. HBV-DNA was found not only in the three HReAg-positive patients but also in two HBsAg-positive patients with serum anti-HRe. in two HBsAg-negative patients with anti-Hk. and in I I with In this study, trace amounts of HBV-DNA were detected in 13 HBsAg-negative carriers. The interpretation of the results of the dot-blot assay graded as trace amounts of HBV-DNA was unequivocal, because the results were consistently reproducible, and dot-blot-positive serum samples were shown to contain HBV-DNA by Southern blot analysis. It was more difficult to interpret biologically these findings. Trace amounts of HBV-DNA were unlikely to be passively transferred from infusions with infected clotting factor concentrates, since the HBV-DNA assays were carried out in serum samples collected a t least 2 weeks after the last infusion with concentrates. The serologic profile of HBV-DNA associated with anti-HBc only, present in two HBsAgnegative carriers, might signal either infection with HBV expressing subliminal serum levels of HBsAg or infection with an HBV strain defective for HBsAg synthesis. The existence of carriers with low serum levels of HBsAg is substantiated by the circumstantial evidence that a small proportion of blood donors with anti-HBc as the only marker of HBV infection transmit hepatitis B to the recipients of their blood donations." Recently, a DNA fragment that hybridized with HBV-DNA was extracted from the liver of an HBsAg-negative, anti-HBc-positive patient, demonstrating the existence of an HBV strain with a mutation within the sequence coding for HBsAg synthesis."
The most intriguing finding of this study was the cooccurrence of serum HBV-DNA in six patients with antiHBs and anti-HBc and in five patients with isolated antiHBs, including two vaccinees. Studies of immunoprophylaxis against HBV have indicated, with some exceptions, correlation of the presence of anti-HBs with immunity to subsequent hepatitis B infections.16 The first such exception was the finding in 1978 of Spero et al, who used an immunofluorescence technique for staining hepatic HBcAg in biopsy samples, that HBsAg-negative hemophiliacs with serum anti-HBs and anti-HBc can harbor replicating HBV.19 Another important exception was the report of well-documented cases of hepatitis B in non-hemophilic patients with preexistent anti-HBs.20.21 These findings suggest that exposure to HBV may lead to convalescent anti-HBs with weak reactivity against subsequent HBV infection. The cooccurrence of HBV-DNA and isolated anti-HBs that we observed in five patients, including two vaccinees, might be explained by infection with HBV-related variants that are immunologically distinct from HBV and do not express core A similar explanation was offered for the occurence of cryptic infection with HBV in successfully vaccinated newborns of chronically infected mothers and in adult family contacts.24 Taken together, these data confirm that in high risk patients vaccination does not give 100% protection against HBV. Whatever the significance of serum HBV-DNA in HBsAg-negative patients with antibodies to HBV, our data corroborate the evidence that HBV may have a greater role in chronic hepatitis of hemophiliacs than previously thought. This biologic profile is not unique to hemophiliacs, since it can also be found in other settings. Recently, HBV-DNA was detected in sera of 68 blood donors with elevated ALT who tested negative for H B s A~.~~ These findings emphasize the importance of serum HBV-DNA as a test for detecting cryptic HBV infection. Assays for serum HBV-DNA should, therefore, be incorporated in the routine check-up of hemophilic patients, to better define the etiology of the underlying liver disease. These assays should also be employed as an adjunct to anti-HBc for detecting cryptic HBV infection in vaccinees. 14. Southern EM: Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol98: 503, 1975 For personal use only. on November 15, 2017. by guest www.bloodjournal.org From
